Novocure vs Transmedics Group
Novocure and Transmedics Group are similar in size: $655m and $605m of revenue in their latest fiscal years. Transmedics Group grew faster (37.1% against 8.3%). Transmedics Group kept more of each dollar of sales as profit: a net margin of 31.4% against -20.8%.
| Latest fiscal year | NovocureNVCR, 2025 | Transmedics GroupTMDX, 2025 |
|---|---|---|
| Revenue | $655m | $605m |
| Revenue growth | 8.3% | 37.1% |
| Net income | −$136m | $190m |
| Operating margin | — | 17.9% |
| Net margin | -20.8% | 31.4% |
| Return on equity | -38.9% | 54.2% |
| Free cash flow | −$75.7m | $134m |
| Cash | $93.5m | $489m |
| Total debt | $195m | $463m |
| Debt to equity | — | 97.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,605 | 898 |
| Market value | $1.56bn | $2.33bn |
| Price vs our value range | — | — |
| Moat score | 36 (Weak) | 33 (Weak) |
| Insider trades, 12 months | 0 buys, 25 sales | 2 buys, 11 sales |